{"id":925684,"date":"2026-01-08T19:02:50","date_gmt":"2026-01-09T00:02:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\/"},"modified":"2026-01-08T19:02:50","modified_gmt":"2026-01-09T00:02:50","slug":"praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\/","title":{"rendered":"Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments"},"content":{"rendered":"
\n

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation\u2013inhibition imbalance, today announced the appointment of Jeffrey B. Kindler and Stuart Arbuckle to its board of directors, and the promotions of Megan Sniecinski to Chief Operating Officer and Dr. Steven Petrou to President of Research & Development.<\/p>\n

\u201cThese leadership decisions reflect a deliberate evolution of Praxis as we enter a phase driven by commercial launch planning and execution readiness, late-stage development, and strategic corporate value optimization,\u201d said Marcio Souza, president and chief executive officer of Praxis. \u201cJeff and Stuart each bring unique and unparalleled experience guiding companies through global commercial launches, pivotal development milestones, and complex strategic transactions. Their perspective significantly enhances our ability to optimize the full range of value-creation pathways for Praxis. At the same time, Megan and Steve have been instrumental in Praxis\u2019s progress to date and are uniquely positioned to expand and scale the organization as Praxis advances into its next phase of maturity and growth.\u201d<\/p>\n

\n Board Appointments<\/strong>\n <\/p>\n

Jeffrey B. Kindler brings exceptional experience in enterprise leadership, capital allocation, and strategic transaction execution across the biopharmaceutical industry. As former chairman and chief executive officer of Pfizer, Mr. Kindler led large-scale R&D and operating model transformations while overseeing major acquisitions and partnerships that reshaped the company\u2019s portfolio and long-term growth trajectory. He is widely recognized for his expertise in public-company leadership and navigating high-stakes strategic decisions. Mr. Kindler currently serves as a director and advisor to multiple healthcare and life sciences companies.<\/p>\n

\u201cPraxis has assembled a rare combination of deep scientific rigor, a highly differentiated CNS pipeline, and a leadership team prepared to make the hard strategic choices required to build a durable biopharmaceutical. As the company enters this next phase, I look forward to working with the board and management team to help position Praxis to continue to create significant value to all stakeholders,\u201d said Mr. Kindler.<\/p>\n

Stuart Arbuckle is a highly accomplished executive with deep experience leading global commercial success at biopharmaceutical organizations. He spent 13 years at Vertex Pharmaceuticals, most recently serving as Executive Vice President and Chief Operating Officer, where he oversaw, among many areas, Vertex\u2019s global commercial, human resources and program, and portfolio management and played a pivotal role in the company\u2019s global growth and scale. Prior to Vertex, Mr. Arbuckle held multiple commercial leadership roles at Amgen and GSK. He currently serves on the boards of directors of Rhythm Pharmaceuticals and Alnylam Pharmaceuticals.<\/p>\n

\u201cPraxis has entered a defining moment, with an exceptional CNS pipeline and the potential to launch multiple transformative medicines in the near term. What excites me most is the opportunity to help shape the company scale at speed and with discipline to deliver these medicines to patients around the world. Drawing on my experience commercializing medicines worldwide and building organizations through periods of rapid growth and change, I look forward to supporting Praxis in this next phase of it’s evolution,\u201d said Mr. Arbuckle.<\/p>\n

\u201cPraxis is uniquely positioned to become the key CNS company in the world, with a set of multi-billion dollar drugs in the near future and an unparalleled pipeline of innovative drugs\u201d said Dean Mitchell, chairman of the Praxis board of directors. \u201cStuart\u2019s comprehensive experience spanning late-stage development and commercial execution together with Jeff\u2019s broad strategic perspective, materially strengthens the board\u2019s ability to guide complex development, commercialization, and strategic decisions with rigor and credibility. This aligns directly with the next phase of Praxis.\u201d<\/p>\n

\n Executive Leadership<\/strong>\n <\/p>\n

Megan Sniecinski, currently Chief Business Officer, has been promoted to Chief Operating Officer. In this role, Ms. Sniecinski will be accountable for operationalizing the company\u2019s growth strategy, overseeing enterprise execution, program strategy and operations, and corporate development. Ms. Sniecinski has been instrumental in shaping Praxis\u2019s strategic positioning, while also playing a principal role in the execution of its late-stage programs including the successful ulixacaltamide Phase 3 program.<\/p>\n

\u201cMegan\u2019s leadership has been a significant driver of Praxis\u2019s success to date,\u201d said Mr. Souza. \u201cAs COO, she is uniquely positioned to guide Praxis through its next phase, driving disciplined execution across development and commercialization, while continuing to evaluate strategic opportunities to maximize shareholder value.\u201d<\/p>\n

Dr. Steven Petrou, currently Chief Scientific Officer, has been promoted to President of Research & Development, reflecting the company\u2019s evolution into a late-stage organization with multiple programs advancing toward registration and commercialization.<\/p>\n

Dr. Petrou is a globally recognized leader in ion channel disease biology and precision medicine and has been a principal architect of Praxis\u2019s scientific foundation, translational engine, and development strategy. As a co-founder of Praxis and as the company has evolved, Dr. Petrou has led the integration of discovery, preclinical, translational, and clinical functions to build a highly differentiated CNS portfolio addressing severe neurological disorders with significant unmet need.<\/p>\n

In this expanded role, Dr. Petrou will continue to oversee the full R&D continuum to maximize the probability of technical and commercial success across the company\u2019s pipeline.<\/p>\n

\u201cSteve\u2019s leadership has been fundamental to building Praxis into the highly productive and scientifically rigorous organization it is today,\u201d said Mr. Souza. \u201cAs we transition into late-stage development and commercial readiness, his expanded role provides the continuity, discipline, and strategic integration required to deliver meaningful value for patients and shareholders.\u201d<\/p>\n

\n About Praxis<\/strong>
\n
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum\u2122, and antisense oligonucleotide (ASO) platform, Solidus\u2122, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit\u00a0www.praxismedicines.com<\/a>\u00a0and follow us on\u00a0Facebook<\/a>,\u00a0LinkedIn<\/a>\u00a0and\u00a0Twitter\/X<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express or implied statements regarding Praxis\u2019 future expectations, plans and prospects, including, without limitation, statements regarding the anticipated timing of our clinical trials, the development of our product candidates and plans to initiate new clinical programs, the anticipated timing of regulatory submissions and interactions and our projected cash runway, as well as other statements containing the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cendeavor,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill\u201d or \u201cwould\u201d and similar expressions that constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995.<\/p>\n

The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical trials; preliminary analyses from ongoing studies differing materially from final data from preclinical studies and completed clinical trials; the expected timing of clinical trials, data readouts and the results thereof, and submissions for regulatory approval or review by governmental authorities; regulatory approvals to conduct trials; and other risks concerning Praxis\u2019 programs and operations as described in its Annual Report on Form 10-K for the year ended December 31, 2024 and as updated in the Quarterly Report on Form 10-Q for the period ended June 30, 2025, as well as other filings made with the Securities and Exchange Commission. Although Praxis\u2019 forward-looking statements reflect the good faith judgment of its management, these statements are based only on information and factors currently known by Praxis. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Praxis undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

\n
Investor Contact:\u00a0\r\nPraxis Precision Medicines\u00a0\r\ninvestors@praxismedicines.com\u00a0\r\n857-702-9452\u00a0\r\n\u00a0\r\nMedia Contact:\r\nDan Ferry\r\nLifeSci Advisors\r\nDaniel@lifesciadvisors.com\r\n617-430-7576<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation\u2013inhibition imbalance, today announced the appointment of Jeffrey B. Kindler and Stuart Arbuckle to its board of directors, and the promotions of Megan Sniecinski to Chief Operating Officer and Dr. Steven Petrou to President of Research & Development. \u201cThese leadership decisions reflect a deliberate evolution of Praxis as we enter a phase driven by commercial launch planning and execution readiness, late-stage development, and strategic corporate value optimization,\u201d said Marcio Souza, president and chief executive officer of Praxis. \u201cJeff and Stuart each bring unique and unparalleled experience … <\/p>\n
Continue reading “Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-925684","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPraxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation\u2013inhibition imbalance, today announced the appointment of Jeffrey B. Kindler and Stuart Arbuckle to its board of directors, and the promotions of Megan Sniecinski to Chief Operating Officer and Dr. Steven Petrou to President of Research & Development. \u201cThese leadership decisions reflect a deliberate evolution of Praxis as we enter a phase driven by commercial launch planning and execution readiness, late-stage development, and strategic corporate value optimization,\u201d said Marcio Souza, president and chief executive officer of Praxis. \u201cJeff and Stuart each bring unique and unparalleled experience … Continue reading "Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-09T00:02:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMjYzMCM3MzUyMzkxIzIyMDA4OTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments\",\"datePublished\":\"2026-01-09T00:02:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\\\/\"},\"wordCount\":1348,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMjYzMCM3MzUyMzkxIzIyMDA4OTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\\\/\",\"name\":\"Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMjYzMCM3MzUyMzkxIzIyMDA4OTY=\",\"datePublished\":\"2026-01-09T00:02:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMjYzMCM3MzUyMzkxIzIyMDA4OTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMjYzMCM3MzUyMzkxIzIyMDA4OTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\/","og_locale":"en_US","og_type":"article","og_title":"Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments - Market Newsdesk","og_description":"BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation\u2013inhibition imbalance, today announced the appointment of Jeffrey B. Kindler and Stuart Arbuckle to its board of directors, and the promotions of Megan Sniecinski to Chief Operating Officer and Dr. Steven Petrou to President of Research & Development. \u201cThese leadership decisions reflect a deliberate evolution of Praxis as we enter a phase driven by commercial launch planning and execution readiness, late-stage development, and strategic corporate value optimization,\u201d said Marcio Souza, president and chief executive officer of Praxis. \u201cJeff and Stuart each bring unique and unparalleled experience … Continue reading \"Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-09T00:02:50+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMjYzMCM3MzUyMzkxIzIyMDA4OTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments","datePublished":"2026-01-09T00:02:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\/"},"wordCount":1348,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMjYzMCM3MzUyMzkxIzIyMDA4OTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\/","name":"Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMjYzMCM3MzUyMzkxIzIyMDA4OTY=","datePublished":"2026-01-09T00:02:50+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMjYzMCM3MzUyMzkxIzIyMDA4OTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMjYzMCM3MzUyMzkxIzIyMDA4OTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-further-positioned-for-next-phase-growth-with-key-board-and-executive-appointments\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/925684","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=925684"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/925684\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=925684"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=925684"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=925684"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}